ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Cervical Cancer

Cervical Cancer

A new paper highlights the global inequities in access to prevention, early detection and treatment for breast cancer and cervical cancer.

The combination of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and nedaplatin showed promising activity and was relatively well tolerated in a small phase II trial.

The human papillomavirus (HPV) vaccine reduces the incidence of pre-cancerous cervical intraepithelial neoplasia (CIN), according to a population-based study in New Mexico.

HIV infection significantly decreases survival among women with invasive cervical cancer, according to a study conducted in Botswana. This was the case even though most women with HIV received antiretroviral therapy.

In this interview we discuss a joint statement from MD Anderson and 68 other NCI-designated cancer centers that calls for increased HPV vaccination for the prevention of cancer.

A concurrent chemotherapy and radiotherapy regimen with cisplatin and paclitaxel yielded a good response rate and strong long-term survival outcomes in patients with locally advanced or recurrent cervical cancer.

A live attenuated bioengineered bacteria-vectored vaccine immunotherapy is well tolerated and appears to be associated with promising overall survival among women with persistent/recurrent metastatic cervical cancer.

Pages

Subscribe to Cervical Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.